title: Zoledronic Acid Improves Bone Quality in the Streptozotocin-Induced Diabetes Rat through Affecting the Expression of the Osteoblast-Regulating Transcription Factors.
abstract: OBJECTIVE
  To evaluate the short term effect of zoledronic acid on bone remodeling in the streptozotocin induced diabetes rats.
  
  
  METHODS
  Diabetes was induced by an injection of streptozotocin (60 mg/kg). The rats were treated with zoledronic acid (0.1 mg/kg) at the onset of diabetes (Z-I group) and 2 weeks later (Z-II group). Rats were sacrificed at the 1, 2, 3, 4 and 5 weeks after the onset of diabetes. Real-time PCR and western blot were performed to detect the expression of the following osteogenic gene mRNAs and their proteins: bone morphogenetic proteins 2 (BMP2), Runx2, Osterix and Noggin. The bone mineral density (BMD) and the mechanical resistance test was measured.
  
  
  RESULTS
  BMP2, Runx2 and Osterix mRNA and protein expression in group D had regulated down, while Noggin expression increased. Z-I treatment could reverse the results. However group Z-II showed only a transient reversing effect. On the 5thweek in group D, the BMD decreased, the bone trabecular distance increased, while the trabecular thickness and bone trabecular volume were reduced, the biomechanics index decreased significantly. Zoledronic acid treatment restored these alterations.
  
  
  CONCLUSIONS
  Zoledronic acid administered in the early stage of the diabetes could prevent the osteopenia. The underlying mechanisms might be that zoledronic acid treatment reversed the effect of diabetes on the expression of osteoblast-regulating transcription factors: BMP2, Runx2 and Osterix.
authors.affiliation: Department of Pain Management, Jinan Central Hospital affiliated to Shandong University, Jinan, People's Republic of China.
authors.forename: M
authors.initials: M
authors.lastname: Cui
authors.affiliation: Department of Pain Management, Jinan Central Hospital affiliated to Shandong University, Jinan, People's Republic of China.
authors.forename: L-Z
authors.initials: LZ
authors.lastname: Yu
authors.affiliation: Department of Pain Management, Jinan Central Hospital affiliated to Shandong University, Jinan, People's Republic of China.
authors.forename: N
authors.initials: N
authors.lastname: Zhang
authors.affiliation: Department of Anesthesiology, Jinan Central Hospital affiliated to Shandong University, Jinan, People's Republic of China.
authors.forename: L-J
authors.initials: LJ
authors.lastname: Wang
authors.affiliation: Department of Pain Management, Binzhou Medical University Hospital, Binzhou, People's Republic of China.
authors.forename: J
authors.initials: J
authors.lastname: Sun
authors.affiliation: Department of Anesthesiology, Wendeng Central Hospital of Wei Hai, Weihai, People's Republic of China.
authors.forename: J
authors.initials: J
authors.lastname: Cong
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D055396:Bone Morphogenetic Protein 2 / Q000187:drug effects* / Q000378:metabolism; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism; D050657:Core Binding Factor alpha Subunits / Q000187:drug effects* / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D051381:Rats; D017208:Rats, Wistar; D014157:Transcription Factors / Q000187:drug effects* / Q000378:metabolism; D000077211:Zoledronic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D000099176:Noggin Protein
chemical_list: D050071:Bone Density Conservation Agents; D055396:Bone Morphogenetic Protein 2; D002352:Carrier Proteins; D050657:Core Binding Factor alpha Subunits; D014157:Transcription Factors; D000077211:Zoledronic Acid; D000099176:Noggin Protein; C525720:Bmp2 protein, rat; C495181:Sp7 protein, rat